Trial intelligence / Profile preview

Pegcetacoplan vs Eculizumab in PNH (PEGASUS)

NCT03500549Phase 3Completed

Sponsor
Apellis Pharmaceuticals
Start
Jun 2018
Primary completion
Nov 2019
Modality
PEGylated Peptides
Countries
11
01

Overview

A Phase 3 trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Started Jun 2018; status: completed.

02

Drugs

pegcetacoplan
03

Conditions

paroxysmal nocturnal hemoglobinuria (PNH)

Beyond the preview

Go deeper on NCT03500549.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03500549.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call